Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
Paris, July 25, 2024
Q2 sales growth of
10.2%
at CER and business EPS
(1)
of €
1.73
Dupixent sales up 29.2% to €3,303 million; target of ~€13 billion in 2024 unchanged
Pharma launches up 80.4% to €689 million, led by ALTUVIIIO, Nexviazyme,...
Zur Pressemeldung auf www.sanofi.com
